Glucocorticoids (GC) are an important part of myeloma therapy; however this therapy stops working with the development of resistance decreasing the effectiveness of this drug. A functional glucocorticoid receptor is frequently missing in GC-resistance; therefore the ability to stimulate the GC-response network in myeloma cells in the absence of receptor may provide a new therapeutic approach. My studies will develop an understanding of the primary targets of the GC signaling network which induce cell death and not the unwanted side effects to provide a means for developing new therapeutic targets which could be effective when traditional GC-based therapies fail.